Therapeutic uses of vitamin D analogues

American Journal of Kidney Diseases

Volumn 38, Issue 5 SUPPL. 5, 2001, Pages

  Brown, A J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Analogues; Cancer; Hypercalcemia; Hyperparathyroidism; Osteoporosis; Psoriasis; Vitamin D

Indexed keywords

20 EPICALCITRIOL; 22 OXACALCITRIOL; 2BETA (3 HYDROXYPROPOXY)CALCITRIOL; ALFACALCIDOL; CALCIPOTRIOL; CALCITRIOL; DOXERCALCIFEROL; LEXACALCITOL; MEMBRANE RECEPTOR; OXYGENASE; PARATHYROID HORMONE; PARICALCITOL; SEOCALCITOL; TACALCITOL; VITAMIN D BINDING PROTEIN; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

ARTICLE; CANCER; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; HUMAN; HYPERCALCEMIA; IMMUNOPATHOLOGY; NONHUMAN; OSTEOARTHRITIS; OSTEOPOROSIS; PSORIASIS; SECONDARY HYPERPARATHYROIDISM; TREATMENT INDICATION;

EID: 0034747728     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2001.28111     Document Type: Article

References (139)

1. 3 and bone metabolism
2. 3 receptor
3. 3 receptors by blocking ubiquitin/proteasome-mediated degradation in human skin
4. 2 as therapeutic agents for prostate cancer
5. 3 receptors on alveolar lymphocytes from patients with pulmonary granulomatous diseases
6. Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo
7. 3 on cellular proliferation
8. 3 receptor expression in N-ethylnitrosourea-induced mouse pulmonary adenomas
9. Vitamin D receptor expression in chicken muscle tissue and cultured myoblasts
10. 3 receptors identified in the rat heart
11. 3: Role of protein kinase C
12. A 1,25-dihydroxyvitamin D receptor-like protein in mammalian and avian liver nuclei
13. 3 receptors in the central nervous system of the rat embryo
14. 3 regulates the expression of VDR and NGF gene in Schwann cells in vitro
15. 3 receptors
16. 2 production by cells of the rheumatoid lesion
17. 3 are associated with enhanced activation of the vitamin D receptor
18. Molecular basis for differential action of vitamin D analogs
19. 3
20. Metabolism and transporting system of 22-oxacalcitriol
21. The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine
22. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion
23. New active analogues of vitamin D with low calcemic activity
24. 3: Effects on cell growth regulation in vitro and calcium metabolism in vivo
25. 3, on the parathyroid glands
26. 3 (analogues) by cytochrome P450 enzyme inhibitors is compound and cell-type specific
27. Metabolism of the vitamin D analogue EB1089 by cultured human cells: Redirection of hydroxylation site to distal carbons of the side-chain
28. EB1089, a novel vitamin D analogue with strong antiproliferative and differentiation-inducing effects on target cells
29. 3 is due to reduced catabolism and altered protein binding
30. Metabolism of 22-oxacalcitriol by a vitamin D-inducible pathway in cultured parathyroid cells
31. 22-Oxa calcitriol is a less potent regulator of keratinocyte proliferation and differentiation due to decreased cellular uptake and enhanced catabolism
32. 3 by normal human peripheral monocytes
33. 3, is equipotent to its parent in modulating growth and differentiation of human leukemic cells
34. 3, exerts immunosuppressive activity equal to its parent without causing hypercalcemia in vivo
35. 3 in kidney: Influence of structural modification of D-ring on side-chain metabolism
36. The vitamin D analog, KH1060, is rapidly degraded both in vivo and in vitro via several pathways: Principal metabolites generated retain significant biological activity
37. 3 through A-ring modification
38. 3
39. Early effects of vitamin D metabolites on phosphate fluxes in isolated rat enterocytes
40. Early stimulation of alkaline phosphatase activity in response to 1alpha,25-dihydroxycholecalciferol
41. Cation-dependent vitamin D activation of human renal cortical guanylate cyclase
42. Early rise in cyclic GMP after 1,25-dihydroxycholecalciferol administration in the chick intestinal mucosa
43. 3 on the phosphoinositide metabolism in rat enterocytes
44. 3
45. 2+ on phospholipid metabolism in dispersed porcine parathyroid cells
46. 3 metabolites on cytosolic free calcium in confluent mouse osteoblasts
47. 3 on cytosolic calcium in dispersed parathyroid cells
48. 2+ priming during vitamin D-induced monocytic differentiation of a human leukemia cell line
49. 3
50. 3 in osteosarcoma cells is independent of calcium influx
51. +2 influx-dependent nongenomic pathways
52. 3
53. 3 and 22-oxacalcitriol in rat osteoblasts, and by casein kinase II, in vitro
54. 3 analogue structure-function assessment of intestinal nuclear receptor occupancy with induction of calbindin-D28K
55. 2+ entry-stimulating pathways
56. 3 are mediated exclusively through the genomic signaling pathway
57. 3
58. 3 modulate the hormone-induced increments in osteocalcin gene transcription in osteoblast-like cells
59. 3 analog structure-function assessment of the rapid stimulation of intestinal calcium absorption (transcaltachia)
60. 3
61. Structure-function relationships in the vitamin D endocrine system
62. 3 analogues
63. 22-Oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure
64. Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism
65. Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: Results of a preliminary study
66. 2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia
67. 2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content
68. 2 prevent high phosphorus-induced parathyroid gland growth in early uremia by inducing p21 and reducing transforming growth factor (TGF-α) expression
69. 2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats
70. 2 (19-nor) on PTH and bone histomorphometry in uremic rats
71. 2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis
72. 2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism
73. 3) therapy for secondary hyperparathyroidism
74. Hectorol: A new vitamin D prohormone
75. 2) in dialysis patients with secondary hyperparathyroidism: A sequential comparison
76. The relationship of solar radiation to cancer mortality in North America
77. Do sunlight and vitamin D reduce the likelihood of colon cancer?
78. Geographic variation in breast cancer mortality in the United States: A hypothesis involving exposure to solar radiation
79. 3, DD-003
80. 3, inhibits azoxymethane-induced colonic tumorigenesis
81. 3
82. 3 analogue, EB1089, inhibits growth of subcutaneous xenografts of the human colon cancer cell line, LoVo, in a nude mouse model
83. A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer
84. Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen
85. 1Alpha, 25-dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat
86. Potentiation of cisplatin antitumor activity using a vitamin D analogue in a murine squamous cell carcinoma model system
87. 3 on the proliferation of pancreatic cancer cell lines
88. Seocalcitol (EB 1089): A vitamin D analogue of anti-cancer potential. Background, design, synthesis, pre-clinical and clinical evaluation
89. Calcitriol in the treatment of postmenopausal osteoporosis
90. 3: Short- and long-term effects on bone and calcium metabolism in patients with postmenopausal osteoporosis
91. Calcitriol treatment is not effective in postmenopausal osteoporosis
92. Treatment of postmenopausal osteoporosis with calcitriol or calcium
93. Long-term treatment with calcitriol in postmenopausal osteoporosis
94. 3
95. Studies of osteoporosis in Japan
96. 3 (ED-71), increases bone mass by stimulating the bone formation in normal and ovariectomized rats
97. Effects of a synthetic vitamin D analogue, ED-71, on bone dynamics and strength in cancellous and cortical bone in prednisolone-treated rats
98. Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo
99. 3 analogue stimulates terminal differentiation and inhibits proliferation of cultured human keratinocytes
100. 3 analogue MC903 on secretion of interleukin-1 alpha (IL-1 alpha) and IL-8 by normal human keratinocytes and a human squamous cell carcinoma cell line (HSC-I)
101. Regulatory effects of antipsoriatic agents on interleukin-1 alpha production by human keratinocytes stimulated with gamma interferon in vitro
102. Origin of the use of calcipotriol in psoriasis treatment
103. Tacalcitol ointment for psoriasis
104. 3 with high activity for inducing epidermal differentiation but decreased hypercalcemic activity
105. 3 with an oxygen atom in their side-chain
106. 3 analogue, OCT, on immunomodulatory function of keratinocytes and lymphocytes
107. 3 and an analogue on normal and psoriatic epidermis in organ culture
108. 3: In vivo and in vitro effects on human preleukemic and leukemic cells
109. 3
110. Treatment of myelodysplastic syndrome with alfacalcidol
111. 3 for prolongation of leukemic transformation-free survival in myelodysplastic syndromes
112. 3 prolongs survival time of leukemic mice
113. The role of vitamin D in immunosuppression: Lessons from autoimmunity and transplantation
114. 3 prolongs skin graft survival in mice
115. Two novel vitamin D analogues, KH 1060 and CB 966, prolong skin allograft survival in mice
116. 3 analogues: Immunosuppressive effects on skin allograft survival
117. 3 analogue 1,25-dihydroxy-delta-16-cholecalciferol
118. 3 prolongs rat cardiac allograft survival
119. A vitamin D analogue with immunosuppressive effects on heart and small bowel grafts
120. 3 analogue KH1060 on the suppression of renal allograft rejection in the rat
121. The effects of combined treatment with the novel vitamin D analogue MC 1288 and cyclosporine A on cardiac allograft survival
122. Vitamin D and prostate cancer
123. 3 on primary cultures of human prostatic cells
124. Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl)retinamide, and the vitamin D analogue Ro24-5531 for androgen-promoted carcinomas of the rat seminal vesicle and prostate
125. Vitamin D receptors and anti-proliferative effects of vitamin D derivatives in human pancreatic carcinoma cells in vivo and in vitro
126. 3 (calcitriol) in hormone-refractory prostate cancer
127. Vitamin D in the prevention and treatment of prostate cancer
128. Vitamin D receptor polymorphisms as markers in prostare cancer
129. Vitamin D and breast cancer: Therapeutic potential of new vitamin D analogues
130. Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro
131. Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D Analogue, EB 1089
132. The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells
133. 3, a potent angiogenesis inhibitor, on rat mammary tumors induced by 7,12-dimethyl-benz[a]anthracene
134. Anti-oestrogen resistant human breast cancer cell lines are more sensitive towards treatment with the vitamin D analogue EB1089 than parent MCF-7 cells
135. Topical calcipotriol treatment in advanced breast cancer
136. A vitamin D analogue (MC 1288) has immunomodulatory properties and suppresses collagen-induced arthritis (CIA) without causing hypercalcaemia
137. Adjacent genes, for COL2A1 and the vitamin D receptor, are associated with separate features of radiographic osteoarthritis of the knee
138. Antiproliferative activity in vitro of side-chain analogues of calcitriol against various human normal and cancer cell lines
139. Vitamin D analogues